Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3120 monotherapy in advanced or metastatic solid tumors
NL-OMON60306Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MK-3120 in Nonhematologic neoplasms, sponsored by Merck & Co. Primary endpoints: Number of participants who experience an adverse event and Number of participants who discontinue study treatment due to an adverse event. Started May 2025; status: recruiting.
02
Drugs
MK-3120
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON60306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60306.